These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36522348)

  • 1. Sequence-specific capture and concentration of viral RNA by type III CRISPR system enhances diagnostic.
    Nemudraia A; Nemudryi A; Buyukyoruk M; Scherffius AM; Zahl T; Wiegand T; Pandey S; Nichols JE; Hall LN; McVey A; Lee HH; Wilkinson RA; Snyder LR; Jones JD; Koutmou KS; Santiago-Frangos A; Wiedenheft B
    Nat Commun; 2022 Dec; 13(1):7762. PubMed ID: 36522348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequence-specific capture and concentration of viral RNA by type III CRISPR system enhances diagnostic.
    Nemudraia A; Nemudryi A; Buyukyoruk M; Scherffius AM; Zahl T; Wiegand T; Pandey S; Nichols JE; Hall L; McVey A; Lee HH; Wilkinson RA; Snyder LR; Jones JD; Koutmou KS; Santiago-Frangos A; Wiedenheft B
    Res Sq; 2022 Apr; ():. PubMed ID: 35475170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrinsic signal amplification by type III CRISPR-Cas systems provides a sequence-specific SARS-CoV-2 diagnostic.
    Santiago-Frangos A; Hall LN; Nemudraia A; Nemudryi A; Krishna P; Wiegand T; Wilkinson RA; Snyder DT; Hedges JF; Cicha C; Lee HH; Graham A; Jutila MA; Taylor MP; Wiedenheft B
    Cell Rep Med; 2021 Jun; 2(6):100319. PubMed ID: 34075364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substrate selectivity and catalytic activation of the type III CRISPR ancillary nuclease Can2.
    Jungfer K; Sigg A; Jinek M
    Nucleic Acids Res; 2024 Jan; 52(1):462-473. PubMed ID: 38033326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interference Requirements of Type III CRISPR-Cas Systems from Thermus thermophilus.
    Karneyeva K; Kolesnik M; Livenskyi A; Zgoda V; Zubarev V; Trofimova A; Artamonova D; Ispolatov Y; Severinov K
    J Mol Biol; 2024 Mar; 436(6):168448. PubMed ID: 38266982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure and mechanism of a Type III CRISPR defence DNA nuclease activated by cyclic oligoadenylate.
    McMahon SA; Zhu W; Graham S; Rambo R; White MF; Gloster TM
    Nat Commun; 2020 Jan; 11(1):500. PubMed ID: 31980625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA targeting by the type III-A CRISPR-Cas Csm complex of Thermus thermophilus.
    Staals RH; Zhu Y; Taylor DW; Kornfeld JE; Sharma K; Barendregt A; Koehorst JJ; Vlot M; Neupane N; Varossieau K; Sakamoto K; Suzuki T; Dohmae N; Yokoyama S; Schaap PJ; Urlaub H; Heck AJ; Nogales E; Doudna JA; Shinkai A; van der Oost J
    Mol Cell; 2014 Nov; 56(4):518-30. PubMed ID: 25457165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specificity and sensitivity of an RNA targeting type III CRISPR complex coupled with a NucC endonuclease effector.
    Grüschow S; Adamson CS; White MF
    Nucleic Acids Res; 2021 Dec; 49(22):13122-13134. PubMed ID: 34871408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Type III CRISPR Ancillary Ribonuclease Degrades Its Cyclic Oligoadenylate Activator.
    Athukoralage JS; Graham S; Grüschow S; Rouillon C; White MF
    J Mol Biol; 2019 Jul; 431(15):2894-2899. PubMed ID: 31071326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type III CRISPR-Cas: beyond the Cas10 effector complex.
    Stella G; Marraffini L
    Trends Biochem Sci; 2024 Jan; 49(1):28-37. PubMed ID: 37949766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virus detection via programmable Type III-A CRISPR-Cas systems.
    Sridhara S; Goswami HN; Whyms C; Dennis JH; Li H
    Nat Commun; 2021 Sep; 12(1):5653. PubMed ID: 34580296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR-Cas Systems: Programmable Nuclease Revolutionizing the Molecular Diagnosis.
    Pandya K; Jagani D; Singh N
    Mol Biotechnol; 2024 Aug; 66(8):1739-1753. PubMed ID: 37466850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reverse Transcription-Loop-Mediated Isothermal Amplification-CRISPR-Cas13a Technology as a Promising Diagnostic Tool for SARS-CoV-2.
    Ortiz-Cartagena C; Fernández-García L; Blasco L; Pacios O; Bleriot I; López M; Cantón R; Tomás M
    Microbiol Spectr; 2022 Oct; 10(5):e0239822. PubMed ID: 36169448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An anti-CRISPR viral ring nuclease subverts type III CRISPR immunity.
    Athukoralage JS; McMahon SA; Zhang C; Grüschow S; Graham S; Krupovic M; Whitaker RJ; Gloster TM; White MF
    Nature; 2020 Jan; 577(7791):572-575. PubMed ID: 31942067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of CRISPR RNA recognition and processing by Cas6 endonucleases.
    Niewoehner O; Jinek M; Doudna JA
    Nucleic Acids Res; 2014 Jan; 42(2):1341-53. PubMed ID: 24150936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tetramerisation of the CRISPR ring nuclease Crn3/Csx3 facilitates cyclic oligoadenylate cleavage.
    Athukoralage JS; McQuarrie S; Grüschow S; Graham S; Gloster TM; White MF
    Elife; 2020 Jun; 9():. PubMed ID: 32597755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CLEVER assay: A visual and rapid RNA extraction-free detection of SARS-CoV-2 based on CRISPR-Cas integrated RT-LAMP technology.
    Bhatt A; Fatima Z; Ruwali M; Misra CS; Rangu SS; Rath D; Rattan A; Hameed S
    J Appl Microbiol; 2022 Aug; 133(2):410-421. PubMed ID: 35396760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR systems: Novel approaches for detection and combating COVID-19.
    Safari F; Afarid M; Rastegari B; Borhani-Haghighi A; Barekati-Mowahed M; Behzad-Behbahani A
    Virus Res; 2021 Mar; 294():198282. PubMed ID: 33428981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Saliva-Based RNA Extraction-Free Workflow Integrated With Cas13a for SARS-CoV-2 Detection.
    Azmi I; Faizan MI; Kumar R; Raj Yadav S; Chaudhary N; Kumar Singh D; Butola R; Ganotra A; Datt Joshi G; Deep Jhingan G; Iqbal J; Joshi MC; Ahmad T
    Front Cell Infect Microbiol; 2021; 11():632646. PubMed ID: 33796478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The CRISPR ancillary effector Can2 is a dual-specificity nuclease potentiating type III CRISPR defence.
    Zhu W; McQuarrie S; Grüschow S; McMahon SA; Graham S; Gloster TM; White MF
    Nucleic Acids Res; 2021 Mar; 49(5):2777-2789. PubMed ID: 33590098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.